Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients

Bone Marrow Transplantation volume 52, pages 1016–1021 (2017)Cite this article

Subjects

Abstract

The annual influenza vaccine is recommended for hematopoietic stem cell transplant (HSCT) patients although studies have shown suboptimal immunogenicity. Influenza vaccine containing an oil-in-water emulsion adjuvant (MF59) may lead to greater immunogenicity in HSCT recipients. We randomized adult allogeneic HSCT patients to receive the 2015–2016 influenza vaccine with or without MF59 adjuvant. Preimmunization and 4-week post-immunization sera underwent strain-specific hemagglutination inhibition assay. We randomized 73 patients and 67 (35 adjuvanted; 32 non-adjuvanted) had paired samples available at follow-up. Median age was 54 years (range 22–74) and time from transplant was 380 days (range 85–8107). Concurrent graft-versus-host disease was seen in 42/73 (57.5%). Geometric mean titers increased significantly after vaccination in both groups. Seroconversion to at least one of three influenza antigens was present in 62.9% vs 53.1% in adjuvanted vs non-adjuvanted vaccine (P=0.42). Factors associated with lower seroconversion rates were use of calcineurin inhibitors (P<0.001) and shorter duration from transplantation (P=0.001). Seroconversion rates were greater in patients who got previous year influenza vaccination (82.6% vs 45.5%, P=0.03). Adjuvanted vaccine demonstrated similar immunogenicity to non-adjuvanted vaccine in the HSCT population and may be an option for some patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Dignani MC, Costantini P, Salgueira C, Jordán R, Guerrini G, Valledor A et al. Pandemic 2009 influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000Res 2014; 3: 221.

    Article  PubMed  Google Scholar 

  2. Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G . H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving. Transpl Infect Dis 2011; 13: 208–212.

    Article  CAS  PubMed  Google Scholar 

  3. Lehners N, Tabatabai J, Prifert C, Wedde M, Puthenparambil J, Weissbrich B et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS ONE 2016; 11: e0148258.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant 2001; 28: 775–781.

    Article  CAS  PubMed  Google Scholar 

  5. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11: 1–5.

    CAS  PubMed  Google Scholar 

  6. Haining WN, Evans JW, Seth NP, Callaway GD, Wucherpfennig KW, Nadler LM et al. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol 2004; 127: 322–325.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 434–438.

    Article  PubMed  Google Scholar 

  8. Ljungman P, Avetisyan G . Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008; 42: 637–641.

    Article  CAS  PubMed  Google Scholar 

  9. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS . The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005; 36: 897–900.

    Article  CAS  PubMed  Google Scholar 

  10. Durando P, Icardi G, Ansaldi F . MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10: 639–651.

    Article  CAS  PubMed  Google Scholar 

  11. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G . MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10: 447–462.

    Article  CAS  PubMed  Google Scholar 

  12. Ellis JS, Zambon MC . Molecular analysis of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 1997; 13: 369–372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  14. Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D et al. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. J Prev Med Hyg 2009; 50: 121–126.

    CAS  PubMed  Google Scholar 

  15. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ . Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly. Clin Vaccine Immunol 2014; 21: 989–996.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation 2016; 100: 662–669.

    Article  CAS  PubMed  Google Scholar 

  17. Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011; 96: 896–904.

    Article  PubMed  PubMed Central  Google Scholar 

  18. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011; 96: 307–314.

    Article  PubMed  Google Scholar 

  19. Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011; 29: 1777–1782.

    Article  CAS  PubMed  Google Scholar 

  20. Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant 2013; 19: 109–116.

    Article  PubMed  Google Scholar 

  21. Avetisyan G, Aschan J, Hassan M, Ljungman P . Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86: 257–263.

    Article  CAS  PubMed  Google Scholar 

  22. Halasa NB, Savani BN, Asokan I, Kassim A, Simons R, Summers C et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant 2016; 22: 528–535.

    Article  CAS  PubMed  Google Scholar 

  23. Ambati A, Boas LS, Ljungman P, Testa L, de Oliveira JF, Aoun M et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant 2015; 50: 858–864.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Author contributions

YN, AH and DK participated in research design, the writing of the paper, the performance of the research and data analysis. JL and DDHK participated in writing of the paper and data analysis. PA and KH participated in the performance of the research.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada

    Y Natori, A Humar, P Ashton & D Kumar

  2. Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

    J Lipton & D D Kim

  3. Public Health England, London, UK

    K Hoschler

Authors
  1. Y Natori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Humar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D D Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Ashton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Hoschler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Kumar.

Ethics declarations

Competing interests

DK has received research funding from Roche and GSK, honoraria from GSK and Sanofi. The remaining authors have no conflicts of interest.

Additional information

Presented in part at IDWeek, New Orleans, 23–27 October 2016.

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Natori, Y., Humar, A., Lipton, J. et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 52, 1016–1021 (2017). https://doi.org/10.1038/bmt.2017.24

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.24

This article is cited by

Search

Advanced search

Quick links